Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study.

Debdulal Chakraborty,Milan Thakkar,Ramesh Venkatesh,Sangeeta Roy,Maulik Bhavsar,Helene Karcher

Clinical ophthalmology (Auckland, N.Z.)（2023）

引用 0|浏览1

暂无评分

摘要

The study reports on the short-term effectiveness and tolerability of brolucizumab therapy in the management of nAMD in both treatment-naïve and switch eyes. Brolucizumab was observed to have a favourable benefit-risk profile, and study results were within the known safety profile, with no instances of intraocular inflammation.

查看译文

关键词

anti-VEGF, brolucizumab, nAMD, real -world evidence, India

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要